Home › Companies › Editas Medicine, Inc. › 2025-2026

Editas Medicine, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Editas Medicine, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

4Ballot items
237Asset managers
841Fund votes
June 17, 2026Meeting date

Results at a glance

Meeting of June 17, 2026: 4 items on Editas Medicine, Inc.’s Form 8-K, filed June 18, 2026: 2 approved · 2 without a stated outcome.

Material dissent

Elect Director: Bernadette Connaughton 73% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Editas Medicine, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Editas Medicine, Inc.

These tallies are Editas Medicine, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Editas Medicine, Inc. — official shareholder meeting results, meeting held June 17, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Bernadette Connaughton	28,660,181	--	--	10,789,549	26,404,190	73%	Not verified	—
Elect Director: Elliott Levy, M.D.	37,095,058	--	--	2,354,672	26,404,190	94%	Not verified	—
2. The compensation paid to its named executive officers	32,914,258	6,322,885	212,587	--	26,404,190	84%	Approved	—
3. The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026	64,686,839	774,471	392,610	--	0	99%	Approved	—

Source: Editas Medicine, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.

How asset managers voted at the Editas Medicine, Inc. 2025-2026 meeting

Each item below shows how the 237 asset managers that disclosed a Editas Medicine, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Bernadette Connaughton

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD

FOR: 28,660,181WITHHELD: 10,789,549

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Bernadette Connaughton

Editas Medicine, Inc.’s own tally for this item (“Elect Director: Bernadette Connaughton”): 28,660,181 for, 10,789,549 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 13,679,209 for, 1,173,183 withheld, 1,827,587 abstained.

FOR

FOR: 13,679,209ABSTAIN: 1,827,587WITHHOLD: 1,173,183

Largest asset managers voting on “Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Bernadette Con” at Editas Medicine, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	7,313,083	61	13,693	For
Fidelity	2,140,598	0	42,900	For
BlackRock	306,602	1,653,431	0	Mixed
TIAA	1,903,318	0	0	For
Charles Schwab	862,565	0	0	For
JPMorgan	588,540	0	0	For
Equitable	0	0	259,336	Withhold
Brighthouse	77,282	0	55,333	Mixed
Lincoln Financial	127,677	0	0	For
BRIDGEWAY FUNDS INC	0	0	126,000	Withhold
SEI	108,986	0	0	For
QUANTITATIVE MASTER SERIES LLC	0	108,885	0	Abstain
AIG/SunAmerica	0	0	104,989	Withhold
Columbia Threadneedle	0	0	95,483	Withhold
Global X	92,273	0	0	For
Nationwide	3,341	0	86,738	Withhold
Voya	0	0	57,070	Withhold
Northern Trust	0	0	55,991	Withhold
T. Rowe Price	0	0	55,067	Withhold
AQR	0	0	41,896	Withhold
Pacific Life	0	0	40,292	Withhold
Bridge Builder Trust	0	39,850	0	Abstain
Goldman Sachs	0	0	37,079	Withhold
Russell Investments	36,657	0	0	For
Invesco	35,570	0	0	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

2. Elect Director: Elliott Levy, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 37,095,058WITHHELD: 2,354,672

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Elliott Levy, M.D.

Editas Medicine, Inc.’s own tally for this item (“Elect Director: Elliott Levy, M.D.”): 37,095,058 for, 2,354,672 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 16,510,339 for, 169,635 withheld, 5 abstained.

FOR

FOR: 16,510,339ABSTAIN: 5WITHHOLD: 169,635

Largest asset managers voting on “Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Elliott Levy, ” at Editas Medicine, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	7,326,832	5	0	For
Fidelity	2,183,498	0	0	For
BlackRock	1,960,033	0	0	For
TIAA	1,903,318	0	0	For
Charles Schwab	862,565	0	0	For
JPMorgan	588,540	0	0	For
Equitable	154,726	0	104,610	Mixed
Brighthouse	123,581	0	9,034	Mixed
Lincoln Financial	127,677	0	0	For
BRIDGEWAY FUNDS INC	126,000	0	0	For
SEI	108,986	0	0	For
QUANTITATIVE MASTER SERIES LLC	108,885	0	0	For
AIG/SunAmerica	104,989	0	0	For
Columbia Threadneedle	95,483	0	0	For
Global X	92,273	0	0	For
Nationwide	90,079	0	0	For
Voya	57,070	0	0	For
Northern Trust	0	0	55,991	Withhold
T. Rowe Price	55,067	0	0	For
AQR	41,896	0	0	For
Pacific Life	40,292	0	0	For
Bridge Builder Trust	39,850	0	0	For
Goldman Sachs	37,079	0	0	For
Russell Investments	36,657	0	0	For
Invesco	35,570	0	0	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

3. 2. The compensation paid to its named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

84% Approved · of votes cast

FOR 84%AGAINST

FOR: 32,914,258AGAINST: 6,322,885

Details: description as filed, official tally, votes by 237 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Editas Medicine, Inc.’s own tally for this item (“2. The compensation paid to its named executive officers”): 32,914,258 for, 6,322,885 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation paid to its named executive officers.”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 46 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Editas Medicine, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	7,326,802	33	1	For
Fidelity	2,140,598	42,900	0	For
BlackRock	1,960,033	0	0	For
TIAA	1,903,318	0	0	For
Charles Schwab	862,565	0	0	For
JPMorgan	588,540	0	0	For
Equitable	154,726	104,610	0	Mixed
Brighthouse	77,282	46,299	9,034	Mixed
Lincoln Financial	127,677	0	0	For
BRIDGEWAY FUNDS INC	0	126,000	0	Against
SEI	108,986	0	0	For
QUANTITATIVE MASTER SERIES LLC	108,885	0	0	For
AIG/SunAmerica	0	104,989	0	Against
Columbia Threadneedle	0	95,483	0	Against
Global X	92,273	0	0	For
Nationwide	28,594	61,485	0	Mixed
Investment Managers Series Trust II	0	64,082	0	Against
Voya	57,070	0	0	For
Northern Trust	0	55,991	0	Against
T. Rowe Price	0	55,067	0	Against
AQR	0	41,896	0	Against
Pacific Life	40,292	0	0	For
Bridge Builder Trust	39,850	0	0	For
Goldman Sachs	37,079	0	0	For
Russell Investments	36,657	0	0	For

Fund voting reports, all 46 managers: 15,782,424 for, 952,656 against, 9,035 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 203 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Editas Medicine, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	3,578,870	1,571	For
GEODE CAPITAL MANAGEMENT, LLC	2,451,963	0	For
Nuveen	1,977,509	0	For
State Street	1,476,818	8,045	For
ACADIAN ASSET MANAGEMENT LLC	0	1,108,735	Against
KENNEDY CAPITAL MANAGEMENT LLC	0	871,149	Against
Charles Schwab	862,751	0	For
Vanguard	657,055	34,006	For
MACKENZIE FINANCIAL CORP	664,662	0	For
Northern Trust	0	533,895	Against
DE Shaw	0	407,973	Against
TRUST CO OF OKLAHOMA	392,550	0	For
AQR	0	350,384	Against
Goldman Sachs	275,004	0	For
MELLON INVESTMENTS Corp	247,091	0	For
T. Rowe Price	0	205,440	Against
AllianceBernstein	0	167,530	Against
JACOBS LEVY EQUITY MANAGEMENT, INC	0	151,743	Against
Green Alpha Advisors, LLC	0	127,495	Against
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	126,000	Against
JPMorgan	121,456	0	For
Allianz	0	118,050	Against
SEI	109,346	0	For
Fidelity	100,133	0	For
STIFEL NICOLAUS & CO INC \MO\	0	98,211	Against

Institutional-manager reports, all 203 managers: 13,489,880 for, 4,950,779 against, 2,770 abstained, 18,381 not voted. Showing the 25 largest; see all in the interactive database.

4. 3. The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%

FOR: 64,686,839AGAINST: 774,471

Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Editas Medicine, Inc.’s own tally for this item (“3. The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 64,686,839 for, 774,471 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 16,735,025 for, 1 against, 9,035 abstained.

FOR

FOR: 16,735,025AGAINST: 1ABSTAIN: 9,035

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at Editas Medicine, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	7,326,835	1	1	For
Fidelity	2,183,498	0	0	For
BlackRock	1,960,033	0	0	For
TIAA	1,903,318	0	0	For
Charles Schwab	862,565	0	0	For
JPMorgan	588,540	0	0	For
Equitable	259,336	0	0	For
Brighthouse	123,581	0	9,034	Mixed
Lincoln Financial	127,677	0	0	For
BRIDGEWAY FUNDS INC	126,000	0	0	For
SEI	108,986	0	0	For
QUANTITATIVE MASTER SERIES LLC	108,885	0	0	For
AIG/SunAmerica	104,989	0	0	For
Columbia Threadneedle	95,483	0	0	For
Global X	92,273	0	0	For
Nationwide	90,079	0	0	For
Investment Managers Series Trust II	64,082	0	0	For
Voya	57,070	0	0	For
Northern Trust	55,991	0	0	For
T. Rowe Price	55,067	0	0	For
AQR	41,896	0	0	For
Pacific Life	40,292	0	0	For
Bridge Builder Trust	39,850	0	0	For
Goldman Sachs	37,079	0	0	For
Russell Investments	36,657	0	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Largest Editas Medicine, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 97,866,996 shares outstanding at the time of that meeting.

Fund voting reports: top Editas Medicine, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	7.49%
2	Fidelity	2.23%
3	BlackRock	2.00%
4	TIAA	1.94%
5	Charles Schwab	0.88%
6	JPMorgan	0.60%
7	Equitable	0.26%
8	Brighthouse	0.14%
9	Lincoln Financial	0.13%
10	BRIDGEWAY FUNDS INC	0.13%

Institutional-manager reports: top Editas Medicine, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE…”, 2025-2026
#	Asset manager	% of shares outstanding
1	BlackRock	3.66%
2	GEODE CAPITAL MANAGEMENT, LLC	2.51%
3	Nuveen	2.02%
4	State Street	1.52%
5	ACADIAN ASSET MANAGEMENT LLC	1.13%
6	KENNEDY CAPITAL MANAGEMENT LLC	0.89%
7	Charles Schwab	0.88%
8	Vanguard	0.71%
9	MACKENZIE FINANCIAL CORP	0.68%
10	Northern Trust	0.55%

Reported Editas Medicine, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Editas Medicine, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Commodore Capital LP	16.40%	13G
TCG Crossover GP III, LLC	16.14%	13G
BlackRock	9.47%	13F
RA Capital Management, L.P.	9.08%	13G
Vanguard Group	8.39%	13F
Renaissance Technologies	4.06%	13F
Geode Capital	2.36%	13F
State Street	2.12%	13F
JPMorgan Chase	1.99%	13F
D.E. Shaw	1.99%	13F

Percentages above are of 97,866,996 shares outstanding, as reported by Editas Medicine, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Editas Medicine, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Editas Medicine, Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 237 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 841 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE… — Editas Medicine, Inc.'s filing reports the proposal as approved, with 84% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Editas Medicine, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.

Editas Medicine, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.